Here are five key notes on the financing:
1. The company completed a $25 million Series D financing round.
2. Endeavour Vision led the round with participation from existing investors Sante Ventures. The additional new investors were Wellington Partners and Gimv.
3. The financing will support several initiatives:
• Expanded commercialization efforts for the company’s minimally invasive GERD therapy outside the United States
• A randomized sham-controlled pivotal trial in the United States
• Next generation device development
4. EndoStim developed neurostimulation therapy for GERD, which affects millions of people worldwide. The device is designed for long-term reflux control by restoring the normal esophageal function through low-energy personalized stimulation.
5. The company currently has an ongoing international patient registry to demonstrate outcomes for abdominal acid control in the esophagus and improvement in patient quality of life.
More articles on gastroenterology:
MACRA proposed rule release: 4 ways it will affect gastroenterologists
Fuse system delivers higher ADR rate than traditional colonoscopies: 3 findings
FDA stops requesting a Custom Ultrasonics endoscope repreocessor recall: 7 key notes
